Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 1999 2009 Prevention of cardiovascular disease in diabetes mellitus - clinical center network. NIH/NHLBI PI
2. 2005 Clinical Evaluation of the Safety and Feasibility of the Investigational BD Continuous Glucose Monitoring Sensor (Becton-Dickinson Research Laboratories) PI
3. 2005 Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients with type 2 diabetes, who are treated with a stable dose of metformin. (Hoffman-LaRoche) PI
4. 2004 A Study of the Safety and Effectiveness of the DexCom Continuous Glucose Monitor in Patients with Type 1 Diabetes Mellitus (DexCom) PI
5. 2004 A Randomized, Double-blind, Placebo Controlled, Rising Dose, Multicenter Study to Evaluate the Safety and Efficacy of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP peptide in Type 1 Diabetes Mellitus Patients. (Quintiles) PI
6. 2004 A Randomized, Double-blind, Placebo Controlled, Rising Dose, Multicenter Study to Evaluate the Safety and Efficacy of 90 Days of 300 or 600 mg Daily Subcutaneous Injections on INGAP peptide in Type 2 Diabetes Mellitus Patients. (Quintiles) PI
7. 2004 Anhydroglucitol (1,5-AG) and Postprandial Hyperglycemia as Measured by Continuous Glucose Monitoring System (CGMS) in Inadequately Controlled Patients with Diabetes (Tomen, Japan) PI
8. 2004 A study of the safety and effectiveness of the DexCom Continuous Glucose Monitor in patients with type 1 diabetes mellitus. (Dexcom) PI
9. 2003 An open-Label Study to Examine the Long Term effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects with Type 2 Diabetes Mellitus (Amylin) PI
10. 2003 A phase 3 randomized, double blind, placebo controlled multicenter trail to evaluate the safety and efficacy of BMS 298585 in combination with metformin therapy in subjects with type 2 diabetes who have inadequate glycemic control on metformin therapy alone. (Bristol Myers Squibb) Co-investigator
11. 2002 Retrospective Study for the Collection of DNA from Patients Previously Enrolled in Study 1014 (Pfizer) PI
12. 2002 12-week, Multinational, Mulitcenter, Controlled Open 1:1:1 Randomized, Parallel Clinical Trial to Assess Noninferiorty Between Pre-and Post -Meal Administration of HMR 1964 and Pre-Meal Regular Human Insulin in Subjects with Type 1 Diabetes Mellitus Receiving Insulin Glargine as the Basal Insulin Therapy (Aventis) Co-investigator
13. 2002 A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled Multicenter Study to Examine the Effect on Glucose Control of AC2993 Given two times a day in subjects with Type 2 Diabetes Mellitus Treated with Metformin Alone (Amylin) PI
14. 2002 A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled Multicenter Study to Examine the Effect on Glucose Control of AC2993 Given two times a day in subjects with Type 2 Diabetes Mellitus Treated with Sulfonylurea Alone (Amylin) PI
15. 2002 A 26-week multinational, mulitcenter, open clinical extension trial to assess 1 year safety of HMR 1964 compared with regular insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH Insulin and previously participating in study HMR 1964-3002 (Aventis) Co-investigator
16. 2002 A Phase 3 Randomized Triple Blind Parallel Group Long Term Placebo Controlled Multicenter Study to Examine the Effect on Glucose Control of AC2993 Given two times a day in subjects with Type 2 Diabetes Mellitus Treated with Metformin and Sulfonylurea (Amylin) PI
17. 2002 A Randomized Triple-Blind Placebo-Controlled Multicenter Study to Investigate the safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects with Type 1 Diabetes (Amylin) PI
18. 2002 The Anthem Study; Advicor in the Treatment of Diabetic Patients with Dyslipidemia Using Thiazolidinedione (KOS) Co-investigator
19. 2002 A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCI vs Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I) (Takeda) PI
20. 2001 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Glucose Control of AC 2993 (0.08/ug/kg) Given Threes Times a Day Versus Twice a Day for 29 Days in Subjects with Type 2 Diabetes Mellitus Treated with Sulfonylureas and/or Metformin (Amylin) Co-investigator
21. 2001 Clinical Effectiveness of the Diasensor 2000 Noninvasive Glucose Meter used in a De-Centralized Environment (Biocontrol) PI
22. 2001 Single dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients (GMP) PI
23. 2000 Cardiovascular Health in Children and Youth (NIH, NINR) Co-investigator
24. 2000 A Randomized, Multi-Center, Placebo Controlled, Double-Blind, Parallel Group Clinical Trial to Assess the Effect of Three Months Repeated Daily Oral 1200 mg Doses of D-Chiro-Inositol (INS-1), in Combination with Oral Sulfonylureas Control and Lipid Profiles in Patients with Type 2 Diabetes. (Insmed) PI
25. 2000 Pioglitazone Versus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus and Dyslipidemia. (Lilly) PI
26. 2000 Safety of Pulmonary Insulin in Patients with Type 2 Diabetes (Lilly) PI
27. 2000 A Long-Term, Double-Blind, Placebo Controlled, Parallel Group Study of Zenarestat (CI-1014) in Diabetic Patients at Risk of Foot Ulcer. (Parke-Davis) PI
28. 2000 A 12-Week, Double-Blind, Placebo-Controlled, Multi-Center Study to Compare the Effect of Zenerstat (CI-1014) with Enalapril on Microalbuminuria in Diabetes Patients. (Parke-Davis) PI
29. 2000 A 12-month, Multi-Center, Open-Label Extension to Protocol 1014-001 to Evaluate the Safety of Zenarestat (CI-1014) in the Treatment of Diabetic Neuropathy. (Parke-Davis) PI
30. 2000 A 20-Week, Double-Blind, Randomized, Active-Controlled, Multicenter Study Comparing Efficacy and Safety of Troglitazone Plus Metformin or Rosiglitazone Plus Metformin to Metformin Plus Placebo in Type 2 Diabetic Patients Not Optimally Controlled on Metformin. (Parke-Davis) PI
31. 2000 A Multicenter, Randomized, Double-Blind, Parallel Group, Clinical Evaluation of Oral GI262570 Sodium Tablets (2.5mg, 5 mg and 7.5mg) in Combination with Metformin for 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus who Are Inadequately Controlled on a Maximum Dose of Metformin. (Glaxo-Wellcome) PI
32. 2000 Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin. (Hoescht Marion Roussel) PI
33. 2000 A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients not Responding to Maximum Dose Metformin and Thiazolininedione (Aventis) PI
34. 2000 A 24 Week, Multicenter, Double-Blind, Randomized, Parallel Group Fixed Dose Study to Prospectively Evaluate the Safety, Efficacy and Tolerability of Nateglinide plus Rosiglitazone Combination Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Prior Rosiglitazone Monotherapy and Diet (Novartis) Co-investigator
35. 2000 Pioglitazone Versus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus And Dyslipidemia (Lilly) PI
36. 1999 Randomized, Double-Blind, Placebo Controlled, Dose-Response Trial of. Akesis Pro Health Pak (proprietary dietary supplement for diabetes and pre-diabetes) in Type 2 Diabetes (Akesis) PI
37. 1999 A Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Investigate the Efficacy and Safety of the Glucagon Receptor Antagonist BAY27-9955 in the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Insulin Therapy (Bayer) PI
38. 1999 A 24-Week, Double-Blind Study of Troglitazone (Rezulin) in Combination with Sulfonylurea or in Combination with Sulfonylurea Plus Metformin in Type 2 Diabetes Patients Inadequately Controlled on Sulfonylurea. (Parke-Davis) PI
39. 1999 A 26-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Rosiglitazone Administered Twice a Day in Combination with a Sulfonylurea and Metformin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled and Sulfonylurea and Metformin (SmithKline Beecham) PI
40. 1998 A 16 Week Multicenter, Controlled, Randomized, Open Label Clinical Trial Comparing HOE 901 Insulin and NPH Human Insulin in Subjects with Type 1 Diabetes Treated with Lispro (Hoechst Marion Roussel) PI
41. 1998 A 24-Week, Double Blind Study of Troglitazone versus Placebo in Patients with Type II Diabetes Mellitus Who Require Insulin (Parke-Davis) PI
42. 1998 Insulin Delivery Using a 3.0mL Disposable Pen Device (Lilly) PI
43. 1998 A Multicenter Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Clinical Evaluation of Oral GI262570X as a Monotherapy for 12 Weeks Duration in Subjects with Type 2 Diabetes Mellitus (Glaxo Wellcome) PI
44. 1998 A 32 Week, Randomized Controlled Trial Evaluating the Efficacy of Self Blood Glucose Monitoring in Patients with Type 2 Diabetes Mellitus (UNC/GCRC) PI
45. 1998 Safety and Efficacy of Fixed Combination Metformin/Glyburide Products as First Line Therapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise (Bristol-Myers Squibb) PI
46. 1998 A 24 Month, Double-Blind, Randomized, Placebo-Controlled, Fixed-Dose, Parallel-Group Multicenter Study of Zenerestat (CI-1014) in the Treatment of Diabetic Neuropathy (Parke-Davis) PI
47. 1997 A Six Month Multicenter, Randomized, Parallel, Open-Label Efficacy and Safety Study Comparison of the Human Insulin Analogue X14 and Regular Human Insulin as Meal Related Insulin in a Multiple Injection Regimen in Subjects with Type II Diabetes (Novo-Nordisk/BioPharm) PI
48. 1997 A 28-Week, Multicenter, Controlled, Randomized Open Clinical Trial Comparing HOE 901 Insulin With NPH Human Insulin in Subjects With. Type I Diabetes (Hoechst Marion Roussel) PI
49. 1997 A 28-Week, Multicenter, Controlled, Randomized Open Clinical Trial Comparing HOE 901 Insulin with NPH Human Insulin in Subjects with Type II Diabetes (Hoescht Marion Roussel) PI
50. 1997 A Six Month Multicenter, Randomized, Parallel, Open-Label Efficacy and Safety Study Comparison of the Human Insulin Analogue X14 and Regular Human Insulin as Meal Related Insulin in a Multiple Injection Regimen in Subjects with Type I Diabetes. (Novo- Nordisk/BioPharm) PI
51. 1997 A Randomized, Double-Blind, P lacebo Controlled, Six-Month Safety and Efficacy Trial of Voglibose (AO-128) 2mg TID and 3mg BID in Type II Diabetes Patients (Quintiles/Takeda) PI
52. 1997 A 4-year, Double-blind, Randomized, Placebo-controlled Study of Atorvastatin as Secondary Prevention of CHD in Patients with (Type II) Noninsulin Dependent Diabetes Mellitus (Parke-Davis, Pfizer) PI
53. 1996 D-chiro-inositol, Pinitol and Myo-inositol Concentrations in Blood and Urine of Individuals with Abnormal Glucose Tolerance (Ross Pharmaceuticals and Abbott Laboratories) PI
54. 1996 A Placebo-controlled Safety and Efficacy Study of Pimagedine in Patients with Type II Diabetes Mellitus and Overt Diabetic Nephropathy (Alteon) PI
55. 1996 (SIP #24-W) Improving Diabetic Care for Minority Women (NIH, PI Dr. T. Keyserling) (NIH Co-investigator
56. 1995 A 20-week, Double-blind, Randomized Study of Troglitazone in Patients with NIDDM (Parke-Davis) PI
57. 1995 P.R.O.T.E.C.T. - PRECOSE (Acarbose Tablets): Resolution of Optimum Titration to Enhance Current Therapies (Bayer) PI
58. 1995 A 31-week, Double-blind Study of Troglitazone (CI-991) Versus Placebo in Noninsulin-Dependent Diabetes Mellitus (NIDDM) Patients Requiring Insulin (Parke-Davis) PI
59. 1994 Pimagedine- Safety and Efficacy in Nephrology of Insulin-dependent Diabetes Mellitus (Alteon) PI
60. 1994 Genetics of Non-insulin Dependent Diabetes (GENNID) Study (American Diabetes Association) PI
61. 1994 Affiliate Center, Insulin-dependent Diabetes Prevention Trial (NIH/NIDDK) Co-PI


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.